Results 241 to 250 of about 218,870 (301)

Spontaneous self-assembly of mangiferin in an aqueous medium into vesicles for anticancer drug encapsulation and antibacterial applications. [PDF]

RSC Adv
Kar S, Patra S, Thaisaeng W, Theppitak C, Thasana N, Bag BG.   +5 more
europepmc   +1 more source

Subtherapeutic exposure in doxorubicin pharmacokinetics among Ugandan breast cancer patients: a pilot study with implications for personalized therapy. [PDF]

BMC Res Notes
Darshit D, Godfrey O, Sekaggya-Wiltshire C, Jackson M, Karyaburo RK, Buzibye A, Omali D, Niyonzima N, Srikant S, Dave D.   +9 more
europepmc   +1 more source

DRAQ7 overcomes the complications associated with autofluorescence of doxorubicin during flow cytometric analyses. [PDF]

Biol Methods Protoc
Çiftçi YC, Erdoğan Vatansever İ, Akgül B.   +2 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

THE HEPATIC PHARMACOKINETICS OF DOXORUBICIN AND LIPOSOMAL DOXORUBICIN

Drug Metabolism and Disposition, 2004
To determine the role of the hepatic sinusoidal endothelium in the hepatic disposition of liposomal doxorubicin, we compared the hepatic pharmacokinetics of doxorubicin hydrochloride and the pegylated, liposomal formulation of doxorubicin (Caelyx). The multiple indicator-dilution technique and electron microscopy were used to study the disposition of ...
Sarah N, Hilmer, Victoria C, Cogger, Michael, Muller, David G, Le Couteur   +3 more
openaire   +2 more sources

Doxorubicin Nanoconjugates

Journal of Nanoscience and Nanotechnology, 2014
Doxorubicin is one of the most widely administered drugs for treatment of cancer. The shortcomings commonly encountered with this drug are severe cardiotoxicity, narrow therapeutic indices, and the development of multiple drug resistance. Hence, several nanoparticulate drug delivery systems have been designed to overcome these limitations and to ...
Kannan, Deepa, Siddhartha, Singha, Tapobrata, Panda   +2 more
openaire   +2 more sources

Liposomal Doxorubicin

Journal of Drug Targeting, 1996
Doxorubicin is a potent antineoplastic agent with activity against numerous human cancers. Encapsulation of doxorubicin inside a liposome alters bioavailability, biodistribution and thus its biological activity significantly. The physical properties of the liposome (size, lipid components and lipid dose) play a major role in determining drug retention ...
P G, Tardi, N L, Boman, P R, Cullis
openaire   +2 more sources

Doxorubicin and the Heart

Annals of Internal Medicine, 1980
Excerpt To the editor: In a recent letter Cosgriff(1) reported onset of ventricular dysrhythmia in a 21-year-old man after administration of doxorubicin and noted the association of doxorubicin, dy...
openaire   +2 more sources

Doxorubicin-heparin complex: reduction of cardiotoxicity of doxorubicin

Journal of Cancer Research and Clinical Oncology, 1995
We have compared the antitumor activity and cardiotoxicity of free doxorubicin (Dox) and doxorubicin-heparin complex in vivo and in vitro. Dox and Dox-heparin complex equally inhibited the DNA synthesis of leukemic cells and showed a similar anticancer activity against tumor-bearing mice.
Y, Mizuno, T, Hara, S, Tachibana, K, Uragoh, K, Akazawa, K, Ueda   +5 more
openaire   +2 more sources

Pharmacokinetics and metabolism of iodo-doxorubicin and doxorubicin in humans

European Journal of Clinical Pharmacology, 1990
The pharmacokinetics of doxorubicin (DOX), iodo-doxorubicin (I-DOX) and their metabolites in plasma has been examined in five patients each receiving 50 mg/m2 of both anthracyclines as a bolus injection. Terminal half-life, mean residence time (MRT), peak plasma concentration Cmax, and area under the curve (AUC) appeared smaller for I-DOX, whereas its ...
K, Mross, U, Mayer, K, Hamm, K, Burk, D K, Hossfeld   +4 more
openaire   +2 more sources